Get Permission Aijaz and Kaur: Speciation and antifungal susceptibility pattern of Candida isolated from blood and body fluids


Introduction

Candidiasis is the commonest fungal disease found in humans affecting mucosa, skin, nails and internal organs. Systemic candidiasis (candidemia) is only seen in severely immunocompromised patients. Candida infection has been associated with many risk factors like long-term hospitalization, increasing use of antibiotic-therapy, use of intravascular catheters and underlying diseases like diabetes, malignancy, AIDS, neutropenia, total parentral nutrition and increased number of patients receiving immunosuppressive therapy for transplantation. Recovery of yeasts from normally sterile body fluids (blood, cerebrospinal fluid, etc), recovery from patients whose defenses were compromised from chronic diseases and repeated recovery from multiple specimens certainly indicates infection with the yeasts.1

Candida albicans is the single most common fungal species causing nosocomial infections. However, non-albicans Candida species, including fluconazole less susceptible Candida glabrata, have become more common pathogens. Main species cassociated with human infections are Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida krusei, Candida dubliniensis and Candida kefyr.2

The ability of the highly adaptable fungal species to transition from commensal to pathogen is due to repertoire of virulence factors that include biofilms, adhesions, enzymes, toxins, Complement receptors and phenotypic switching.3

Various clinical samples that can be collected from patients of candidiasis depend upon the site of infection like oral swab from whitish plaques present on mucous membrane of mouth in AIDS patients, vaginal swabs from patients of vulvovaginitis, skin scraping and nail clipping in patients of cutaneous infections, urine from diabetic and catherised patients, sputum from patients of pulmonary candidiasis, blood from septicemic neonates etc.4 As drug resistance in Candida species is now very common, therefore antifungal susceptibility testing should be performed by determining the MICs. This can play major role in management of resistant candidal infections, particularly caused by Non-albicans Candida species.

Aim & Objectives

  1. Isolation and identification of Candida species of blood and body fluids.

  2. Antifungal susceptibility testing of Candida isolates.

Materials and Methods

The present study was conducted in Mycology section of Microbiology laboratory under Department of Microbiology for period of six months after getting approval from Institutional Research committee and ethics committee.

All blood, CSF, Peritoneal, pleural, Synovial, pericardial fluid and BAL samples received in Microbiology Department for culture were included in the study. Clinical data of patients was collected from patient’s files. The blood and body fluid samples received in the bacteriology laboratory was inoculated into the Bact/Alert standard aerobic bottles and incubated in this system while the other samples were directly inoculated on Sabouraud dextrose agar (SDA) and blood agar and put in glucose broth for further subculture. The inoculated bottles loaded into the Bact/Alert were incubated for a maximum period of 5 days. Bottles flagging as positive by the Bact/Alert instrument were Subcultured on SDA media slope and blood agar and incubated at 37°C. Cultures were examined after overnight incubation and every day in first week and than twice a week for evidence of growth. Culture were hold for up to 4 weeks before being declared as negative. Identification was done on the basis of colony characters, LCB preparation and gram staining. C. albicans produced medium sized 1.5mm diameter, circular smooth and grayish white colored colonies, C, tropicalis produced large grey mycelia fringe colonies, C. krusei produced 0.2-1.0mm diameter, small, round or irregular, flat or heaped colonies. Gram positive budding yeast cells with pseudohyphae were seen on Gram staining and in LCB preparation showed 4-7um budding yeast cells with pseudohyphae.4 Germ tube test is used to differentiate between albican and non-albican Candida.4

The Vitek 2 compact system was used for final identification of non-albican Candida using yeast identification card. Antifungal susceptibility was done by using YST08 cards in Vitek 2 Compact which uses spectrophotometric readings to determine an MIC value for clinically relevant Candida species. The cards contain wells with dried concentrations of antifungal drugs in medium. After the isolate was adjusted to a standardized concentration in saline, it was used to rehydrate the drug wells and the card was placed into a Vitek 2 card reader/incubator, The growth within each well was monitored up to 36 hrs (an average of 12 to 14 hour) by an optical scanner and a report containing an MIC value along with the interpretive category for each antifungal on the card was generated. The drugs tested for antifungal susceptibility by using YST08 cards include Amphotericin B, Fluconazole, Voriconazole Micafungin Caspofungin and Flucytosine.

Results

A total of 735 clinical samples were received. Out of which 53 (7.21%) Candida species were isolated from various clinical samples like: Blood, Pericardial fluid, peritoneal fluid, Cerebrospinal fluid, Pleural fluid and BAL in bacteriology laboratory of Microbiology department over a period of six months. Out of 53 patients with Candida species, female patients were 24 (45.29%) and male patients were 29(54.71%).Table 1 shows that the maximum number of patients belonged to age group >60 years, followed by 41-60years age group among both males and females. Out of 53 isolates, 17 were from intensive care Unit (ICU), 14 were from department of medicine, 9 were from Cardiac care Units (CCU), 6 from department of pediatrics, 4 were from department of surgery, and 3 were from the department of Pulmonary medicine. Table 2 shows that the maximum number of species were obtained from blood 23 (43.39%), followed by pleural fluid 14 (26.4%), pericardial fluid 6 (11.32%), bronchial fluid 5 (9.43%), peritoneal fluid 3(5.66%) and cerebrospinal fluid 2(3.8%). Among 53 isolates 24 were C. albicans and 29 were non albican Candida spp. Table 2 shows C. albicans 24(45.3%) was obtained as most common species followed by C. tropicalis 11(20.75%), C. glabrata 9(16.98%), C. parapsilosis 7(13.20%) and C. krusei 2(3.77%). Antifungal susceptibility pattern of Candida spp. (Table 3) indicates that C. albicans maximum sensitivity to Amphotericin B (91.67%) followed by micafungin (79.17%), caspofungin (75%), flucytosine (70.83%), voriconazole (66.67%) and fluconazole (62.5%). Antifungal susceptibility pattern of C. tropicalis, C. glabrata and C. parapsilosis was as shown in Table 3.

Table 1

Age wise distribution of patients with Candida species

Age group (years)

Female no. (%)

Male no. (%)

0-10

3 (5.7%)

2 (3.77%)

11-20

2 (3.77%)

2 (3.77%)

21-40

6 (11.32%)

4 (7.54%)

41-60

6 (11.32%)

10 (18.86%)

>60

7 (13.20%)

11. (20.75%)

Total

24 (45.31%)

29 (54.69%)

Table 2

Species wise distribution of Candida species

Species

No. of isolates

Percentage

C. albicans

24

45.3%

C. tropicalis

11

20.75%

C. glabrata

9

16.98%

C. parapsilosis

7

13.20%

C. krusei

2

3.77%

Total

53

100%

Table 3

Antifungal susceptibility pattern of albicans and non-albicans Candida

Antifungal agents

C. albicans (n=24)

C. tropicalis (n=11)

C. glabrata (n=9)

C. parapsilosis (n=7)

Sen

Resis

Sen

Resis

Sen

Resis

Sen

Resis

Amphotericin B

22 (91.67%)

2 (8.33%)

10 (90.9%)

1 (9.1%)

9 (100%)

0 (0%)

7 (100%)

0 (0%)

Fluconazole

15 (62.5%)

9 (37.5%)

4 (36.4%)

7 (63.6%)

0 (0%)

9 (100%)

1 (14.3%)

6 (85.7%)

Voriconazole

16 (66.67%)

8 (33.33%)

7 (63.6%)

4 (36.4%)

6 (66.7%)

3 (33.3%)

6 (85.7%)

1 (14.3%)

Micafungin

19 (79.17%)

5 (20.83%)

8 (72.7%)

3 (27.3%)

3 (33.3%)

6 (66.7%)

4 (57.1%)

3 (42.9%)

Caspofungin

18 (75%)

6 (25%)

9 (81.8%)

2 (18.2%)

4 (44.4%)

5 (55.6%)

3 (42.9%)

4 (57.1%)

Flucytosine

17 (70.83%)

7 (29.17%)

8 (72.7%)

3 (27.3%)

7 (77.8%)

2 (22.2%)

5 (71.4%)

2 (28.6%)

Discussion

The Candida species which were considered as normal flora component is now responsible for the endogenous infections and various systemic infections. It is found mainly as secondary cause of infection in individuals with some underlying immunocompromised conditions and very rarely as primary pathogen.

In the present study the higher prevalence of Candida species was seen in males, which coincides well with the Gupta et al5 where as much higher prevalence shown by Xess et al6 and lower prevalence shown by Singh and Abraham.7 It is concluded that males are more prone to Candida infection because of poor hygiene, diabetes and prolonged use of antibiotics and the yeast like fungus form normal commensal of oral, mucosal, gastrointestinal and genitourinary tract of human. In the present study, the age of patients ranged from 0-79 years. Among them >60 years age group was most common age group affected followed by 41-60 years and then 21-40 years (Table 1). Deorukhar and Saini (2012) and Shaik et al. (2016) reported greater number of patients with >60 year age group.8, 9 It is concluded that high incidence of systemic candidiasis is among old age as compared to children and adults. The aging population is especially susceptible to fungal infection due to underlying medical conditions and increase in the rates of hospitalization. From the above study, it is concluded that Candida is most commonly isolated from blood sample as compared to other samples because Candida species is fourth most common nosocomial pathogen causing 11% of all bloodstream infections. The result of the present study (43.39%) are nearby Palwa et al (24.5%) where as lower prevalence was shown by Gandhi and Patel (7.14%), Arora et al. (9.36%).10, 11, 12 In the present study, C. albicans (45.3%) showed higher prevalence followed by C. tropicalis, (20.75%), C. glabrata (16.98%), C. parapsilosis (13.20%) and C. krusei (3.77%)(Table 2).

Dharvad and Dominic (2011) showed higher prevalence by C. albicans (47%) followed by C. tropicalis (30%), C.krusei (14%) and C. glabrata (9%).8, 13

Deorukhkar and Saini (2012) and Gupta et al. (2015) showed higher prevalence by C. albicans.5 Chander et al. (2013) and Kaur et al (2014) showed higher prevalence by C. tropicalis.8, 14 showed higher prevalence by C. albicans (50%) followed by C. glabrata (25%), C. krusei (17%) and C. tropicalis (8%).5 In the present study, C. albicans showed maximum sensitivity to Amphotericin B (91.67%) followed by micafungin (79.17%), caspofungin (75%), flucytosine (70.83%), voriconazole (66.67%) and fluconazole (62.5%).(Table 3)

C. albicans showed maximum resistance to fluconazole (37.5%) followed by voriconazole (33.33%) flucytosine (29.17%), caspofungin (25%), micafungin (20.83%) and amohotericin B (8.33%).(Table 3). Chander J. et al. (2013) in their study on 27 Candida species obtained higher sensitivity to Amphoterici (100%) and higher resistance to fluconazole (62%) as compared to our study among c. albicans species.15 Kaur et al (2014) in their study on 103 Candida species obtained higher resistance to fluconazole (68%) and low resistance to Amphotericin (5%) as compared to our study among C. albicans species.14 Gupta et al. (2915) in their study on 12 Candida species obtained higher resistance to Fluconazole (33%), voriconazole (17%) and less resistance Amphotericin B as compared to our study among C. albicans.5

The resistance to fluconazole is of great concern because it is most common azole used for treatment of disseminated candidiasis including candidemia. Increasing use of fluconazole had led to predominance of Non-albicans Candida species over C. albicans. Resistance to voriconazole, micafungin, caspofungin and flucytosine was also seen in our study due to decreased susceptibility to fluconazole and cross resistance to other azoles.

Conclusion

Systemic candidiasis includes a spectrum of yeast infections caused by different species of Candida. The most common form of this invasive infection is Candidemia though it can affect heart, lungs, brain, eyes, bones and other body part. Systemic candidiasis is usually treated with oral or intravenous (IV) antifungal medications like Caspofungin, Fluconazole and Amphotericin B and early diagnosis and antifungal susceptibility testing is necessary for starting appropriate treatment timely.

Source of Funding

None.

Conflict of Interest

None.

References

1 

N Martins ICFR Ferreira L Barros S Silva M Henriques Candidiasis: Predisposing factors, prevention, diagnosis and alternative treatmentMycopathologia20141775-622340

2 

MA Pfaller GJ Moet SA Messer RN Jones M Castanheira Candida bloodstream infections; comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance ProgramAntimicrob Agents Chemother20085525616

3 

JCO Sardi L Scorzoni T Bernardi AM Fusco-Almeida MJSM Giannini Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic optionJ Med Microbiol201362Pt 11024

4 

J Chander Characteristic of fungi In: A text book of Medical Mycology3rd edMehta PublishersNew Delhi19951422

5 

P Gupta S Prateek B Chatterjee A Kotwal AK Singh G Mittal Prevalence of candidemia in ICU in a tertiary care hospital in North IndiaInt J Curr Microbiol Appl Sci2015656675

6 

I Xess N Jain F Hasan Epidemiology of candidaemia in a tertiary care centre of North India: 5 year studyInfection200735256265

7 

N Singh J Abrahim Incidence of Candida in patients admitted to ICUAdv Appl Sci Res2013452826

8 

C Deorukhakar S Saini Non albicans candida species: a rewiew of epidemiology, pathogenicity and antifungal resistancePravara Med Rev20157315

9 

N Shaik U Penmetcha RB Myneni P Yarlagadda S Singamsetty The study of identification and antifungal susceptibility pattern of candida species isolated from various clinical specimens in a tertiary care hospital, Chinakakani, Gyntur, AP, South IndiaInt J Curr Microbiol and Appl Sci2016577191

10 

N Pahwa R Kumar S Nirkhiwala A Bandi Species distribution and drug susceptibility of Candida in clinical isolates from a tertiary care-centre at IndoreIndian J Med Microbiol2014321448

11 

V Gandhi M Patel Prevalance of Candida species and its antimicrobial susceptibility isolated from blood culture at a tertiary care hospitalInt J Current Microbiol Appl Sci20176688492

12 

S Arora N Dhuria N Jindal Speciation, biofilm formation and Antifungal susceptibility of Candida isolatesInt J Res Dev Pharm Life Sci201762251721

13 

S Dharwad RM Dominic Species identification of Candida isolates in various clinical specimen with their antifungal susceptibility patternJ Clin Diagn Res201156117781

14 

R Kaur R Goyal MS Dhakad P Bhalla R Kumar Epidemiology and virulence determinants including biofilm profile of Candida infections in an ICU in a Tertiary Hospital in IndiaJ Mycol201410.1155/2014/303491

15 

J Chander N Single SK Sidhu S Gombar Epidemiology of Candida blood stream infections: experience of a tertiary care centre in North IndiaJ Infect Dev Ctries2013796705



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 10-03-2023

Accepted : 03-04-2023


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijmr.2023.003


Article Metrics






Article Access statistics

Viewed: 1120

PDF Downloaded: 337